# Cambridge Cognition Holdings appoints Richard Bungay to the Board

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-holdings-appoints-richard-bungay-to-the-board/412858340
- Published: 2020-09-14T07:20:46+01:00
- Author: Giles Arbor

**Cambridge Cognition Holdings plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has announced
that Richard Bungay will join the Board as a Non-Executive Director with immediate
effect.

Mr. Bungay has over 25 years’ experience in corporate roles with R&D-based companies
within the biotechnology and pharmaceutical sector, including as CFO of both public
and private companies, with a particular focus on financing, investor relations 
and business development. Richard is currently CFO of Diurnal Group plc, the AIM
quoted specialty pharmaceutical company targeting patient needs in chronic endocrine(
hormonal) diseases.

Prior to that, Richard was CFO and Chief Operating Officer of Mereo BioPharma Group
plc, a biopharmaceutical company focused on rare and specialty diseases. Richard’s
other experience includes being CFO of Glide Technologies, a device and development
company focused on solid dose formulations of therapeutics and vaccines, and CFO
of Verona Pharma plc, a drug development company focused on first-in-class medicines
to treat respiratory diseases. 

Richard qualified as a Chartered Accountant with Deloitte in 1993.

Cambridge Cognition is a neuroscience technology company developing digital health
products to better understand, detect and treat conditions affecting brain health.
The Company’s software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and improve
global efficiency in pharmaceutical and healthcare industries.

Share on:
